Autres langues Gilead Sciences, Inc. Deutsche Boerse AG

Actions

GIS

US3755581036

Produits pharmaceutiques

Marché Fermé - Deutsche Boerse AG 17:24:53 07/08/2026 Varia. 5j. Varia. 1 janv.
115,46 EUR +2,36% Graphique intraday de Gilead Sciences, Inc. +2,14% +9,28%

Autres langues

07/08 Gilead Sciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
05/08 Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says
05/08 Gilead Sciences : Second Quarter 2026 Summary of Remarks
04/08 Gilead Sciences Swings to 2Q Loss on R&D Costs, HIV-Drug Sales Lift Revenue
04/08 Gilead Sciences Q2 Swings To Adjusted Loss, Revenue Rises
04/08 Gilead: Q2 Earnings Snapshot
04/08 (GILD) Gilead Sciences Expects Full Year 2026 Adjusted Loss Range of $0.30 - $0.65, vs. FactSet Est of $0.75 Loss
04/08 Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q2 Revenue $7.80B, vs. FactSet Est of $7.40B
04/08 Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q2 Adjusted Loss $6.75 per Share, vs. FactSet Est of $-7.26
04/08 Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q2 Adjusted Loss $6.75 per Share, vs. FactSet Est of $-7.26
04/08 CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
04/08 Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on August 7, 2025.
04/08 Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.
04/08 Gilead second-quarter sales rise 8%, beating Wall Street estimates
04/08 Gilead Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08 Gilead Sciences, Inc. Declares Dividend for the Third Quarter of 2026, Payable on September 29, 2026
04/08 Gilead Sciences, Inc. Revises Earnings Guidance for the Full Year 2026
04/08 Equities Rally Intraday Amid Upbeat Earnings, Hormuz Reopening Hopes
04/08 Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says
04/08 Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
04/08 Morning Meeting: Wall Street entdeckt die "Magnificent Seven" wieder
04/08 Wall Street Reconnects with the Magnificent Seven
04/08 Pathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical
03/08 Bedrijfskalender van 3 tot 7 augustus 2026
03/08 Máximo tribunal de California falla a favor de Gilead en caso sobre el "deber de innovar"
Aucun résultat pour cette recherche